$3.25+ Bn Human Microbiome Market Trends and Global Forecasts, 2035, Driven by Advancements in Microbiome Sequencing, Rising Investments in R&D, and Increasing Demand for Personalized Medicine
Dublin, Feb. 16, 2026 (GLOBE NEWSWIRE) -- The "Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions" report has been added to ResearchAndMarkets.com's offering.
The human microbiome market is estimated to grow from USD 0.85 billion in the current year to USD 3.27 billion by 2035, at a CAGR of 16% during the forecast period, till 2035.
The human microbiome consists of a variety of microorganisms, such as bacteria, archaea, viruses, and fungi, that inhabit different regions of the human body, including the skin, gut, mouth, and other tissues. The investigation into the diversity of the human microbiome dates back to the 1680s, when Antonie van Leeuwenhoek examined his oral and fecal microbiota samples.
The existing human microbiome landscape is extremely dynamic, with studies emphasizing its crucial function in immunity, metabolism, and conditions like cancer, inflammatory diseases, and even neurodegenerative disorders. The US FDA has authorized two fecal microbiota treatments to prevent recurring C. difficile infection (rCDI). Significantly, REBYOTA (created by Ferring Pharmaceutical) became the first human microbiome therapy to gain approval in November 2022, with VOWST (developed by Seres Therapeutics) also receiving approval for oral administration in April 2023. Notably, the commercial triumph of VOWST has been strengthened by Nestle Health Science's purchase of its US and worldwide rights in June 2024.
Given the continuous advancements in DNA sequencing, bioinformatics, and analytical tools that enhance our comprehension of the human microbiome in relation to health and diseases, we anticipate that this sector is poised for double-digit market growth in the near future.
Growth Drivers: Strategic Enablers of Market Expansion
Advancements in microbiome sequencing technologies, such as next-generation sequencing and metagenomics, enable deeper analysis of microbial communities, accelerating diagnostics and therapies. Further, rising investments from pharma, biotech firms, and venture capital supports expanding clinical pipelines for conditions like gastrointestinal disorders, metabolic diseases, and cancer. In addition, increasing awareness of the role of microbiome in health, coupled with demand for personalized probiotics, preventive healthcare, and collaborations between startups and academia, further propels human microbiome market expansion.
Market Challenges: Critical Barriers Impeding Progress
While the global human microbiome market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. High R&D and commercialization costs in the human microbiome market space including GMP facilities for live organisms and complex clinical trials, hinder scalability and adoption. Stringent regulatory requirements, lack of standardized guidelines, and variability in microbial strains delay approvals and increase entry barriers across regions. Limited public understanding, ethical concerns over microbiome manipulation, and slow patient / provider adoption due to inconsistent evidence also impede progress.
Human Microbiome Market: Key Insights
Key Attributes:
Primary Research Overview
Companies Featured
Additional Benefits
For more information about this report visit https://www.researchandmarkets.com/r/q7iouw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment